IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was ...

Presenting new clinical data from Phio's on-going Phase 1b trialMarlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio ...

Idaho murder suspect Bryan Kohberger returns to court Thursday, where his defense hopes to have the death penalty taken off ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

We are pleased to partner with Ocugen with this financing as the Company drives its next chapter of growth, based on its novel scientific platforms and dedication to fighting blindness diseases,” said ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...

Botensilimab is an investigational human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive ... Approximately 1,100 patients have been treated with botensilimab in phase 1 ...